Original Investigation May 15, 2022 Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial James W. F. Catto, Pramit Khetrapal, Federico Ricciardi, et al JAMA. Published online May 15, 2022. doi:10.1001/jama.2022.7393 Key Points Question  Does robot-assisted surgery improve periopera...

CORRESPONDENCE Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults Patrick E. Brown, Sze Hang Fu, Aiyush Bansal, et al N Engl J Med May 18, 2022DOI: 10.1056/NEJMc2202879 TO THE EDITOR: The incidence of the omicron BA.1/1.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which rapidly spread worldwide even among vaccinated persons, is incompletely defined.1 We quantified the incidence of SARS-CoV-2 infection d...

ARTICLES|ONLINE FIRST Alcoholic chlorhexidine skin preparation or triclosan-coated sutures to reduce surgical site infection: a systematic review and meta-analysis of high-quality randomised controlled trials National Institute of Health Research Unit on Global Surgery Lancet Infect Dis Published:May 26, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00133-5 Summary Background WHO and the UK's National Institute for Health and Care Excellence recommen...

ORIGINAL ARTICLE Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al N Engl J Med May 25, 2022DOI: 10.1056/NEJMoa2118946 Abstract BACKGROUND Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides natural immunity against reinfection. Recent studies have shown waning of the immunity provided by the BNT162b2 vaccine. The time course of natural and hybrid immuni...

ARTICLES|ONLINE FIRST Global impact of the first year of COVID-19 vaccination: a mathematical modelling study Oliver J Watson, Gregory Barnsley, Jaspreet Toor, et al Lancet Infect Dis Published:June 23, 2022 DOI: https://doi.org/10.1016/S1473-3099(22)00320-6 Summary Background The first COVID-19 vaccine outside a clinical trial setting was administered on Dec 8, 2020. To ensure global vaccine equity, vaccine targets were set by the COVID-19 Vaccines G...

Original Investigation May 17, 2022 Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial Jicheng Lv, Muh Geot Wong, Michelle A. Hladunewich, et al JAMA. 2022;327(19):1888-1898. doi:10.1001/jama.2022.5368 Key Points Question  What are the effects of oral glucocorticoids in patients with IgA nephropathy and proteinuria of 1 g per day o...

CORRESPONDENCE Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron Emma K. Accorsi, Amadea Britton, Nong Shang, et al N Engl J Med May 25, 2022DOI: 10.1056/NEJMc2203165 TO THE EDITOR: For persons who received a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson–Janssen) against coronavirus disease 2019 (Covid-19), a booster dose of a messenger RNA (mRNA) vaccine at least 2 months after the primary dose is recommended. R...

ARTICLES|ONLINE FIRST Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis Nicolò Girometti, Ruth Byrne, Margherita Bracchi, et al Lancet Infect Dis Published: July 01, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00411-X Summary Background Historically, human monkeypox virus cases in the UK have been limited to imported infections f...

Original Investigation May 17, 2022 Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial The UK TAVI Trial Investigators JAMA. 2022;327(19):1875-1887. doi:10.1001/jama.2022.5776 Key Points Question  Is transcatheter aortic valve implantation (TAVI) noninferior to surgical aortic valve replacement (surgery) in patien...

ORIGINAL ARTICLEFREE PREVIEW Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A Margareth C. Ozelo, Johnny Mahlangu, K. John Pasi, et al N Engl J Med 2022; 386:1013-1025DOI: 10.1056/NEJMoa2113708 Abstract BACKGROUND Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)–based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter. The efficacy and safety of the...